European Journal of Clinical Pharmacology

, Volume 24, Issue 4, pp 441–447 | Cite as

The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: A comparison of responders and non-responders

  • M. L. McFadyen
  • P. I. Folb
  • R. Miller
  • I. N. Marks
  • M. G. Moshal
Originals
Received:
Accepted:

Summary

The pharmacokinetics of orally administered ranitidine were studied in 17 male patients with chronic duodenal ulceration. The patients were divided into 2 groups, 10 responders and 7 nonresponders, on the basis of their endoscopic response to ranitidine treatment. The 10 responders were studied both after a single 150 mg dose (SD) and after multiple dosing (MD) with ranitidine 150 mg twice daily for 4 weeks. The area under the curve (AUC) and maximum concentration (Cmax) were significantly higher (p<0.01 andp<0.05, respectively) after MD than after SD, but the half-life (t1/2) and minimum concentration (Cmin) 12 h postdosing did not differ. The non-responders were studied after MD only and their pharmacokinetic characteristics were compared with those of responders. No differences between the 2 groups were found. However, 2 non-responders had particularly low plasma ranitidine levels and high acid output. Such patients may need larger doses of ranitidine for adequate suppression of gastric acid. Five patients (4 responders and 1 non-responder) received ranitidine 20 mg i.v. The drug followed a two-compartment model, with mean values for t1/2β, volume of distribution steady-state and total plasma clearance of 80 min, 701 and 680 ml/min, respectively. The oral bioavailability of ranitidine in these 5 patients showed wide variation (27–76%; mean 51%).

Key words

ranitidine duodenal ulceration pharmacokinetics non-responders therapeutic response bioavailability 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Daly MJ, Humphray JM, Stables R (1980) Inhibition of gastric acid secretion in the dog by the H2-receptor antagonists, ranitidine, cimetidine and metiamide. Gut 21: 408–412Google Scholar
  2. 2.
    Daly MJ, Humphray JM, Stables R (1981) Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine. Br J Pharmacol 72: 49–54Google Scholar
  3. 3.
    Berstad A, Kett K, Aadland E, Carlsen E, Frislid K, Saxhaug K, Kruse-Jensen A (1980) Treatment of duodenal ulcer with ranitidine, a new histamine H2 receptor antagonist. Scand J Gastroenterol 15: 637–639Google Scholar
  4. 4.
    Moshal MG, Spitaels JM, Kahn F (1981) A double-blind endoscopically controlled trial of ranitidine in a high incidence area. Scand J Gastroenterol 16 [Suppl 69]: 129–131Google Scholar
  5. 5.
    Dobrilla G, Barbara L, Bianchi Porro G, Felder M, Mazzacca G, Miglioli L, Pera A, Petrill M, Sabbatini F, Verme G (1981) Placebo controlled studies with ranitidine in duodenal ulcer. Scand J Gastroenterol 16 [Suppl 69]: 101–105Google Scholar
  6. 6.
    Langman MJS, Henry DA, Bell GD, Burnham WR, Ogilvy A (1980) Cimetidine and ranitidine in duodenal ulcer. Br Med J 281: 473–474Google Scholar
  7. 7.
    Boyd EJS, Peden NR, Browning MCK, Saunders JHB, Wormsley KG (1981) Clinical and endocrine aspects of treatment with ranitidine. Scand J Gastroenterol 16 [Suppl 69]: 81–83Google Scholar
  8. 8.
    Henry DA, MacDonald JA, Kitchingman G, Bell GD, Langman MJS (1980) Cimetidine and ranitidine: a comparison of effects on hepatic drug metabolism. Br Med J 281: 775–777Google Scholar
  9. 9.
    Marks IN, Wright JP, Denyer M, Hatfield A, Girdwood AH, Lucke W (1982) Ranitidine heals duodenal ulcers. S Afr Med J 61: 152–154Google Scholar
  10. 10.
    Carey PF, Martin LE (1979) A high performance liquid chromatography method for the determination of ranitidine in plasma. J Liquid Chromatogr 2 [9]: 1291–1303Google Scholar
  11. 11.
    Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New YorkGoogle Scholar
  12. 12.
    Peden NR, Richards DA, Saunders JHB, Wormsley KB (1979) Pharmacologically effective plasma concentrations of ranitidine. Lancet 2: 199–200Google Scholar
  13. 13.
    Garg DC, Weidler DJ, Baltoclano N, Eshelman FN (1981) Pharmacokinetics of ranitidine, a new histamine H2-receptor blocker (Abstract). Clin Pharmacol Ther 29 [2]: 247–248Google Scholar
  14. 14.
    Louis WJ, Mihaly GW, Hanson RG, Anderson A, McNeel JJ, Yeomans ND, Smallwood RA (1981) Pharmacokinetic and gastric secretory studies of ranitidine in man. Scand J Gastroenterol 16 [Suppl 69]: 11–15Google Scholar
  15. 15.
    Woodings EP, Dixon GT, Harrison C, Carey P, Richards DA (1980) Ranitidine — a new H2-receptor antagonist. Gut 21: 187–191Google Scholar
  16. 16.
    Veng Pedersen, Miller R (1980) Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 69 [4]: 394–398Google Scholar
  17. 17.
    Somogyi A, Rohner HG, Gugler R (1980) Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet 5: 84–94Google Scholar
  18. 18.
    Moshal MG, Spitaels KM, Kahn F, Mason J, Naidoo V, Schlemmer L (1982) Factors affecting duodenal ulcer healing. S Afr Med J 61: 202–206Google Scholar
  19. 19.
    Korman MG, Hansky J, Merrett AC, Schmidt GT (1981) Ranitidine in duodenal ulcer: healing rate and effect of smoking. Gastroenterology 80: 1197Google Scholar
  20. 20.
    Roberts DM, Wilson JA, Ratcliffe GE, Waring AJ, Reilly MJ, Lloyd JS (1982) Clinical trial of ranitidine in the treatment of peptic ulcer. Br J Clin Pract 36 [1]: 9–12Google Scholar
  21. 21.
    McFadyen ML, Folb PI, Marks IN, Wright JP, Lucke W (1981) The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration. Scand J Gastroenterol 16 [Suppl 69]: 109–112Google Scholar
  22. 22.
    Binder HJ, Cocco A, Crossley RJ, Finkelstein W, Font R, Friedman G et al. (1978) Cimetidine in the treatment of duodenal ulcer. A multicentre double blind study. Gastroenterology 74: 380–388Google Scholar
  23. 23.
    Rune SJ, Hesselfeldt P, Larsen NE (1979) Clinical and pharmacological effectiveness of cimetidine in duodenal ulcer patients. Scand J Gastroenterol 14: 489–492Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • M. L. McFadyen
    • 1
  • P. I. Folb
    • 1
    • 4
  • R. Miller
    • 2
  • I. N. Marks
    • 1
  • M. G. Moshal
    • 3
  1. 1.Departments of Pharmacology and MedicineUniversity of Cape TownSouth Africa
  2. 2.Pharmacology DepartmentPotchefstroom UniversitySouth Africa
  3. 3.Gastrointestinal UnitUniversity of Natal Medical SchoolDurbanSouth Africa
  4. 4.Department of PharmacologyGroote Schuur Hospital Medical School ObservatoryCape TownSouth Africa

Personalised recommendations